Clinical trial NCT01261585: Study of the Fixation of Various Vectors in PET/CT in Patients With a With Lung Cancer Before and During of CRT or RT
Official title: Study of the Modification of the Fixation of FDG, F-Miso and FLT Measured in PET/CT at Patients Before and in the Course of Exclusive Radiotherapy or Concomitant Radiochemotherapy for Primitive Bronchial Cancer
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Bronchial Neoplasms
Carcinoma, Non-Small-Cell Lung
Keywords: Positron-Emission Tomography
PET Scan
FDG
FLT
FMISO
Non-Small-Cell Lung Carcinoma
chemo-Radiation Oncology
SUV
Lead sponsor: Centre Henri Becquerel
Sponsor class: OTHER
First posted: 2010-12-16
Enrollment: 5
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Diagnosed patients with non-small-cell lung carcinoma

Brief summary: Study of the modification of the fixation(binding) of Fluoro-2-deoxy-D-glucose (FDG), fluoro-misonidazole (FMISO) and 3'deoxy-3-fluoro-thymidine deoxy-3-fluoro-thymidine (FLT) measured in tomography by broadcast(emission,issue) of positrons (PET) at patients before and in the course of exclusive radiotherapy or concomitant radiochemotherapy for primitive bronchial cancer.

This protocle allows to study the simultaneous variations of the metabolism, the hypoxie and the cellular proliferation by PET SCAN at 5 patients reached(affected) by a primitive bronchial cancer in the course of exclusive radiotherapy for primitive bronchial cancer not small cell lung.

The investigators are also going to study several scenarii of optimization of the radiotherapy according to the variations of the tumoral metabolism, the hypoxie and the cellular proliferation measured in the course of radiotherapy (theoretical study on console using the scanner and the various examinations).


Eligibility criteria: Inclusion Criteria:

* patients with non-small-cell lung carcinoma hitologicaly proved
* Candidate patients in a treatment with aim guardian by exclusive thoracic radiotherapy or of concomitant radiochemotherapy (tumoral dose superior to 60 Gy) ( n=5 ).
* Measurable tumor according to the criteria of evaluation RECIST

Exclusion Criteria:

* Histology other one than primitive bronchial cancer not in small cells lung
* The patients for whom no tumoral target is assessable (forgiveness completes after first chemotherapy, operated patients).
* Patients for whom a radiotherapy with curative aim is not indicated (tumoral extension, metastases, general state, co-morbidity).
* Patient having benefited from an examination PET in the FDG with in more than 4 weeks and for which a new PET in the FDG is not necessary with in the framework of its disease

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Rouen
country: France
facility: Centre Henri Becquerel
state: Hate Normandie
Study officials:
affiliation: CHBecquerel
name: GUERNOU Mohamed, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: CHBecquerel
name: VERA Pierre, MD phD
role: STUDY_DIRECTOR
References:
citation: Ganem J, Thureau S, Gardin I, Modzelewski R, Hapdey S, Vera P. Delineation of lung cancer with FDG PET/CT during radiation therapy. Radiat Oncol. 2018 Nov 12;13(1):219. doi: 10.1186/s13014-018-1163-2.
citation: Calais J, Thureau S, Dubray B, Modzelewski R, Thiberville L, Gardin I, Vera P. Areas of high 18F-FDG uptake on preradiotherapy PET/CT identify preferential sites of local relapse after chemoradiotherapy for non-small cell lung cancer. J Nucl Med. 2015 Feb;56(2):196-203. doi: 10.2967/jnumed.114.144253. Epub 2015 Jan 8.